Skip to main content

Question for Department of Health

UIN HL176, tabled on 9 June 2014

To ask Her Majesty's Government what steps they are taking to ensure that recommendations by the Clinical Priorities Advisory Group on theprescription of Duodopa for people with Parkinson's have been developed with public and patient engagement.

Answered on

16 June 2014

The operation of the Clinical Priorities Advisory Group (CPAG) is a matter for NHS England. NHS England has advised that the CPAG is chaired by a lay member and has four public members as part of its core membership.

The draft policy on Duodopa was developed by the Neurosciences Clinical Reference Group, which has four patient/carer members. Registered patient and public stakeholders had an opportunity to share their views and comment on this draft policy before it was considered by CPAG.

CPAG has made recommendations to NHS England. NHS England's decision on whether Duodopa should be routinely commissioned will be subject to 12 weeks public consultation.